John Libbey Eurotext

Hématologie

Lymphomes folliculaires de haut risque et rechute précoce après immunochimiothérapie : apport de l’idélalisib Volume 23, numéro 4, Juillet-Août 2017

  • [1] The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Sfudy Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
  • [2] Casulo C., Byrtek M., Dawson K.L. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33:2516-2522.
  • [3] European Medical Association. ZYDELIG (idélalisib tablets). Product information. 2016. http://www.ema.europa.eu/ema/index.jsp?curl5pages/medicines/human/medicines/003843/human_med_001803.jsp&mid5WC0b01ac058001d124. Accessed 29 November 2016.
  • [4] Gopal A.K., Kahl B.S., de Vos S. PI3Kd inhibition by idélalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008-1018.
  • [5] Gopal A.K., Kahl B.S., Flowers C.R. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017;129:3037-3039.